1KA Stock Chart & Stats
€24.20
€0.40(1.69%)
At close: 4:00 PM EDT
€24.20
€0.40(1.69%)
Day’s Range― - ―
52-Week Range€9.80 - €27.00
Previous CloseN/A
Volume0.00
Average Volume (3M)18.00
Market Cap
€1.70B
Enterprise Value€1.43K
Total Cash (Recent Filing)€362.65M
Total Debt (Recent Filing)€360.00K
Price to Earnings (P/E)―
Beta0.75
Next Earnings
Nov 05, 2026EPS Estimate
-0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.00
Shares Outstanding68,642,290
10 Day Avg. Volume51
30 Day Avg. Volume18
Financial Highlights & Ratios
PEG Ratio-3.01
Price to Book (P/B)2.77
Price to Sales (P/S)0.00
P/FCF Ratio-17.75
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€37.17Price Target Upside53.59% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-1.04
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Balance Sheet And Very Low LeverageExtremely low debt and a growing equity base provide durable financial flexibility to fund multi-stage clinical programs without immediate refinancing. This reduces bankruptcy and liquidity risk, supporting the company’s ability to execute pivotal trials and maintain R&D pacing over the next 2–6 months.
Promising Phase 2a Efficacy In Postpartum DepressionRobust, rapid and sustained clinical signal in a Phase 2a cohort increases scientific credibility and de-risks the program relative to competitors. If replicated in larger pivotal trials, these durable efficacy and functional benefits could meaningfully strengthen GH Research’s market position in rapid-acting psychiatric treatments.
Regulatory Progress: FDA Sees CMC/device Phase‑3 Ready; Doses SelectedWritten FDA feedback on CMC and device readiness and pre-selection of pivotal doses materially reduces late-stage technical and regulatory uncertainty. This improves the likelihood of timely pivotal initiation in 2026 and allows the company to focus resources on trial execution and endpoints rather than major CMC/device rework.
Bears Say
Pre-revenue Business Model With Widening LossesLack of product revenue means the company must continually fund operations through capital markets. Accelerating losses expand capital needs and heighten execution risk: sustained negative profitability increases reliance on financing and raises the stakes for upcoming pivotal results.
Negative And Increasing Operating Cash Flow / Cash BurnPersistent and rising operating cash burn constrains runway and forces management to prioritize financing and spend allocation. Even with a strong balance sheet today, continued negative cash flow narrows strategic flexibility and increases vulnerability to adverse trial outcomes or market dislocations.
Dependence On Equity Markets Via $200M At-the-market OfferingAn ATM facility signals structural reliance on equity financing to fund development. While it provides optionality, ongoing use risks meaningful dilution, especially if share issuance accelerates during periods of weakness, and creates execution risk if capital markets become less receptive.
GH Research News
1KA FAQ
What was GH Research’s price range in the past 12 months?
GH Research lowest stock price was €9.80 and its highest was €27.00 in the past 12 months.
What is GH Research’s market cap?
GH Research’s market cap is €1.70B.
When is GH Research’s upcoming earnings report date?
GH Research’s upcoming earnings report date is Nov 05, 2026 which is in 67 days.
How were GH Research’s earnings last quarter?
GH Research released its earnings results on Aug 06, 2026. The company reported -€0.197 earnings per share for the quarter, beating the consensus estimate of -€0.245 by €0.048.
Is GH Research overvalued?
According to Wall Street analysts GH Research’s price is currently Undervalued.
Does GH Research pay dividends?
GH Research does not currently pay dividends.
What is GH Research’s EPS estimate?
GH Research’s EPS estimate is -0.27.
How many shares outstanding does GH Research have?
GH Research has 68,642,290 shares outstanding.
What happened to GH Research’s price movement after its last earnings report?
GH Research reported an EPS of -€0.197 in its last earnings report, beating expectations of -€0.245. Following the earnings report the stock price went up 3.252%.
Which hedge fund is a major shareholder of GH Research?
Currently, no hedge funds are holding shares in DE:1KA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
GH Research Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€37.17 (53.59% Upside)
€37.17 (53.59% Upside)
Blogger Sentiment
Bullish
DE:1KA Sentiment 100%
Sector Average ―
Sector Average ―
Technicals
SMA
Positive
20 days / 200 days
Momentum
88.26%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
18.80%
Trailing 12-Months
Company Description
GH Research
GH Research PLC is a clinical-stage biopharmaceutical firm dedicated to creating novel therapies for psychiatric and neurological conditions. The company primarily concentrates on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) treatments, specifically targeting patients with treatment-resistant depression (TRD). Its most advanced program is GH001, an inhalable 5-MeO-DMT product candidate that has successfully completed two Phase 1 clinical trials and a subsequent Phase 1/2 clinical trial in TRD patients. Additionally, GH Research is developing GH002, an injectable 5-MeO-DMT candidate, and GH003, an intranasal 5-MeO-DMT candidate. Both GH002 and GH003 are currently in preclinical development, with a focus on their potential applications in various psychiatric and neurological disorders. Founded in 2018, GH Research PLC is headquartered in Dublin, Ireland.
1KA Stock 12 Month Forecast
Average Price Target
€37.17
▲(53.59% Upside)
Technical Analysis
Relay Therapeutics
―
Taysha Gene Therapies
―
Sana Biotechnology
―
Pharming Group
―
Prime Medicine, Inc.
―